<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>EAPSI:  Asymmetric Phase-Transfer Catalyzed Stetter Reaction</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>06/01/2010</AwardEffectiveDate>
<AwardExpirationDate>05/31/2011</AwardExpirationDate>
<AwardTotalIntnAmount>5617.00</AwardTotalIntnAmount>
<AwardAmount>5617</AwardAmount>
<AwardInstrument>
<Value>Fellowship Award</Value>
</AwardInstrument>
<Organization>
<Code>01090000</Code>
<Directorate>
<Abbreviation>O/D</Abbreviation>
<LongName>Office Of The Director</LongName>
</Directorate>
<Division>
<Abbreviation>OISE</Abbreviation>
<LongName>Office Of Internatl Science &amp;Engineering</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Anne Emig</SignBlockName>
<PO_EMAI>aemig@nsf.gov</PO_EMAI>
<PO_PHON>7032927241</PO_PHON>
</ProgramOfficer>
<AbstractNarration/>
<MinAmdLetterDate>06/07/2010</MinAmdLetterDate>
<MaxAmdLetterDate>06/07/2010</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.079</CFDA_NUM>
<NSF_PAR_USE_FLAG>0</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>1015525</AwardID>
<Investigator>
<FirstName>Kevin</FirstName>
<LastName>Oberg</LastName>
<PI_MID_INIT>M</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Kevin M Oberg</PI_FULL_NAME>
<EmailAddress/>
<PI_PHON>5074698584</PI_PHON>
<NSF_ID>000551296</NSF_ID>
<StartDate>06/07/2010</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Oberg                   Kevin          M</Name>
<CityName>Fort Collins</CityName>
<ZipCode>805254530</ZipCode>
<PhoneNumber/>
<StreetAddress/>
<StreetAddress2/>
<CountryName>United States</CountryName>
<StateName>Colorado</StateName>
<StateCode>CO</StateCode>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>CO02</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM/>
<ORG_LGL_BUS_NAME/>
<ORG_PRNT_DUNS_NUM/>
</Institution>
<Performance_Institution>
<Name><![CDATA[Oberg                   Kevin          M]]></Name>
<CityName>Fort Collins</CityName>
<StateCode>CO</StateCode>
<ZipCode>805254530</ZipCode>
<StreetAddress/>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Colorado</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>02</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>CO02</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>7316</Code>
<Text>EAPSI</Text>
</ProgramElement>
<ProgramReference>
<Code>5921</Code>
<Text>JAPAN</Text>
</ProgramReference>
<ProgramReference>
<Code>5978</Code>
<Text>EAST ASIA AND PACIFIC PROGRAM</Text>
</ProgramReference>
<ProgramReference>
<Code>7316</Code>
<Text>EAPSI</Text>
</ProgramReference>
<Appropriation>
<Code>0110</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2010~5617</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reaction development is of vital interest to organic chemistry as these reactions are the tools used to construct molecules of synthetic and medicinal importance. Catalytic methods are attractive because they are atom economical, reduce waste generation, and can be rendered asymmetric to generate large quantities of enantioenriched material. The focus of this research visit was to expand the scope of asymmetric phase-transfer catalysis pioneered by Professor Keiji Maruoka. We employed the catalysts developed in the Maruoka group to the synthesis of 1,4-benzoxazine-3-one derivatives that have been shown to be renin inhibitors by Pfizer.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During my time in the Maruoka group over the summer, two catalysts were synthesized, one of which was novel. The substrate, catalyst, and reaction conditions were optimized to generate a benzoxazinone derivative in enantioselectivities that are synthetically useful. The development of a new phase-transfer catalyst offers the possibility to make a variety of 1,4-benzoxazine-3-one derivatives that may show activity as renin inhibitors. In addition, this catalyst may be used in similar phase-transfer reactions, where it could have different reactivity than previously developed catalysts.</p> <p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; My time in Kyoto, Japan taught me many new things. First, the research area was phase-transfer catalysis and this was very different from the my training in transition-metal catalysis. This presented different problems and solutions and taught me new approaches to chemistry. The mentors had different training and I was exposed to new ideas and new ways to analyze results. This training will help over the course of my career because I will be able to use a larger number of techniques, problem solving skills, and I now have a greater appreciation of research conducted in different cultural settings.</p><br> <p>            Last Modified: 06/14/2011<br>      Modified by: Kevin&nbsp;M&nbsp;Oberg</p> </div> <div class="porSideCol"></div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[             Reaction development is of vital interest to organic chemistry as these reactions are the tools used to construct molecules of synthetic and medicinal importance. Catalytic methods are attractive because they are atom economical, reduce waste generation, and can be rendered asymmetric to generate large quantities of enantioenriched material. The focus of this research visit was to expand the scope of asymmetric phase-transfer catalysis pioneered by Professor Keiji Maruoka. We employed the catalysts developed in the Maruoka group to the synthesis of 1,4-benzoxazine-3-one derivatives that have been shown to be renin inhibitors by Pfizer.              During my time in the Maruoka group over the summer, two catalysts were synthesized, one of which was novel. The substrate, catalyst, and reaction conditions were optimized to generate a benzoxazinone derivative in enantioselectivities that are synthetically useful. The development of a new phase-transfer catalyst offers the possibility to make a variety of 1,4-benzoxazine-3-one derivatives that may show activity as renin inhibitors. In addition, this catalyst may be used in similar phase-transfer reactions, where it could have different reactivity than previously developed catalysts.              My time in Kyoto, Japan taught me many new things. First, the research area was phase-transfer catalysis and this was very different from the my training in transition-metal catalysis. This presented different problems and solutions and taught me new approaches to chemistry. The mentors had different training and I was exposed to new ideas and new ways to analyze results. This training will help over the course of my career because I will be able to use a larger number of techniques, problem solving skills, and I now have a greater appreciation of research conducted in different cultural settings.       Last Modified: 06/14/2011       Submitted by: Kevin M Oberg]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
